SCHEMBL3580512

SCHEMBL3580512

COC(=O)CCCCCC(O)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 3/20 0.57
FFAR1 O14842 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.53
TSHR P16473 3/20 0.52
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
PABPC1 P11940 1/20 0.46
APOBEC3A P31941 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
TET2 Q6N021 3/20 0.43
KDM4A O75164 2/20 0.43
KDM4C Q9H3R0 2/20 0.43
KDM2A Q9Y2K7 2/20 0.43
TET3 O43151 1/20 0.43
PPARG P37231 1/20 0.43
SLC1A1 P43005 1/20 0.42
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579935 1.00 GPR84 (0.57) GPR84FFAR1L3MBTL1TSHRLMNA
SCHEMBL3573769 0.98 TSHR (0.54) GPR84FFAR1L3MBTL1TSHRLMNA
SCHEMBL27797971 0.85 L3MBTL1 (0.53) L3MBTL1TSHRLMNAALDH1A1PABPC1
SCHEMBL14436820 0.84 TET2 (0.56) GPR84FFAR1L3MBTL1TSHRLMNA
SCHEMBL4717704 0.84 TET2 (0.56) GPR84FFAR1L3MBTL1TSHRLMNA
SCHEMBL2562678 0.82 L3MBTL1 (0.54) L3MBTL1TSHRLMNAALDH1A1PABPC1
SCHEMBL3601913 0.82 TSHR (0.58) L3MBTL1TSHRLMNAALDH1A1PABPC1
SCHEMBL16845263 0.82 TSHR (0.58) L3MBTL1TSHRLMNAALDH1A1PABPC1
SCHEMBL28672736 0.82 TSHR (0.58) L3MBTL1TSHRLMNAALDH1A1PABPC1
SCHEMBL28709667 0.82 TSHR (0.58) L3MBTL1TSHRLMNAALDH1A1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113504-A1 AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-05-06 US disclosed
US-20100113504-A1 AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-05-06 US disclosed
US-20100113504-A1 AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-05-06 US disclosed
CN-101641341-A Amide compounds and their use as antitumor agents SIGMA TAU IND FARMACEUTI IT 2010-02-03 CN disclosed
EP-2137169-A1 AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2009-12-30 EP disclosed
WO-2008110583-A1 AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-09-18 WO disclosed
WO-2008110583-A1 AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113504-A1 AMIDE COMPOUNDS AND THEIR USE AS ANTITUMOR AGENTS HDAC3, HCCS, CCNH GPR84 2156/4885FFAR1 1459/4885L3MBTL1 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.